UPC_APP_68658/2024

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Procedural & sub-applicationsDocument Access (RoP262)Milan CDGenericCase Closed

Overview Decisions Citations Documents Timeline

Parties

Claimants

STADAPHARM GmbH

Reps: Phillip Rektorschek

Respondents

Accord Healthcare B.V.
Accord Healthcare S.L.U.
ACCORD HEALTHCARE LIMITED,
Novartis AG

Reps: Gregory Bacon (Bristows LLP); Wim Maas (Taylor Wessing N.V.)

Judges

Andrea Postiglione
Marije Knijff
Oliver Werner

Patents

EP2501384

CPC codes: A61P11/06, A61P37/06, A61P43/00, A61P17/00, A61P9/12, A61K31/506, A61P17/06, A61P19/02, A61P25/28, A61P35/00, A61K31/505, C07D239/69…

Sector: Organic Chemistry

Outcome

Dismissed

Filed: Dec 30, 2024

First decided: Feb 3, 2025

Language: English

Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP (separate application number for the same underlying proceedings UPC_CFI_698/2024, Milan Central Division). Outcome identical to companion order: STADAPHARM's request to access documents was dismissed; NOVARTIS's request for legal cost compensation was dismissed. This appears to be the same decision issued under a different application reference number.

Open on UPC Registry